cgp-48664 has been researched along with Agranulocytosis* in 1 studies
1 trial(s) available for cgp-48664 and Agranulocytosis
| Article | Year |
|---|---|
A phase I study of a new polyamine biosynthesis inhibitor, SAM486A, in cancer patients with solid tumours.
Because tumour cell proliferation is highly dependent upon up-regulation of de-novo polyamine synthesis, inhibition of the polyamine synthesis pathway represents a potential target for anticancer therapy. SAM486A (CGP 48664) is a new inhibitor of the polyamine biosynthetic enzyme S-adenosylmethionine decarboxylase (SAMDC), more potent and specific than the first-generation SAMDC inhibitor methylglyoxal (bis) guanylhydrazone (MGBG). Preclinical testing confirmed promising antiproliferative activity. In this phase I study, SAM486A was given 4-weekly as a 120 h infusion. 39 adult cancer patients were enrolled with advanced/refractory disease not amenable to established treatments, PS Topics: Adenosylmethionine Decarboxylase; Adult; Aged; Agranulocytosis; Amidines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Area Under Curve; Dose-Response Relationship, Drug; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Indans; Male; Middle Aged; Neoplasms; Polyamines; Radiopharmaceuticals; Time Factors; Tomography, Emission-Computed | 2000 |